Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide

References

• Schubert MM, Correa ME. Oral graft-versus-host disease. Dent Clin North Am. 2008;52:79–109.
   PubMedGoogle Scholar
• Imanguli MM, Alevizos I, Brown R, et al. Oral graft-versus-host disease. Oral Dis. 2008;14:396–412.
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Cooke KR, Pan L, et al. The immunopathophysiology of acute graft-versus-host-disease. Stem Cell. 1996;14:473–489.
   PubMed Web of Science ®Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Blazar BR, Cutler C, et al. B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:16–23.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–615.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100:415–419.
   PubMed Web of Science ®Google Scholar
• Treister N, Duncan C, Cutler C, et al. How we treat oral chronic graft-versus-host disease. Blood. 2012;120:3407–3418.
   PubMed Web of Science ®Google Scholar
• Bassim CW, Fassil H, Mays JW, et al. Oral disease profiles in chronic graft versus host disease. J Dent Res. 2015;94:547–554.
   PubMed Web of Science ®Google Scholar
• Elad S, Zadik Y, Zeevi I, et al. Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence. Transplant. 2010;90:1243–1244.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: v. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375–396.
   PubMed Web of Science ®Google Scholar
• Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252–266.
   PubMed Web of Science ®Google Scholar
• Meier JK, Wolff D, Pavletic S, et al. Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Invest. 2011;15:127–139.
   PubMed Web of Science ®Google Scholar
• Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease. Brit J Haematol. 2012;158:46–61.
   PubMed Web of Science ®Google Scholar
• Dignan FL, Scarisbrick JJ, Cornish J, et al. Organ-specific management and supportive care in chronic graft-versus-host disease. Brit J Haematol. 2012;158:62–78.
   PubMed Web of Science ®Google Scholar
• Elad S, Jensen SB, Raber-Durlacher JE, et al. Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. Support Care Cancer. 2015;23:1615–1622.
   PubMed Web of Science ®Google Scholar
• Martin PJ, Lee SJ, Przepiorka D, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant. 2015;21:1343–1359.
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015;21:1167–1187.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group Report. Biol Blood Marrow Transplant. 2015;21:984–999.
   PubMed Web of Science ®Google Scholar
• Paczesny S, Hakim FT, Pidala J, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: iii. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant. 2015;21:780–792.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: i. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015;21:389–401.
   PubMed Web of Science ®Google Scholar
• Kuten-Shorrer M, Woo SB, Treister NS. Oral graft-versus-host disease. Dent Clin North Am. 2014;58:351–368.
   PubMedGoogle Scholar
• Czerninski R, Zadik Y, Kartin-Gabbay T, et al. Dietary alterations in patients with oral vesiculoulcerative diseases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117:319–323.
   PubMed Web of Science ®Google Scholar
• Imanguli MM, Pavletic SZ, Guadagnini JP, et al. Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:175–183.
   PubMed Web of Science ®Google Scholar
• Albuquerque R, Khan Z, Poveda A, et al. Management of oral graft versus host disease with topical agents: a systematic review. Med Oral Patol Oral Cir Bucal. 2016;21:e72–81.
   PubMed Web of Science ®Google Scholar
• Park AR, La HO, Cho BS, et al. Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease. Am J Health Syst Pharm. 2013;70:1383–1391.
   PubMed Web of Science ®Google Scholar
• Elad S, Zeevi I, Finke J, et al. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide – an open, randomized, multicenter study. Biol Blood Marrow Transplant. 2012;18:134–140.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease – management with topical corticosteroids: (2) protocols, monitoring of effects and adverse reactions, and the future. J Dent Res. 2005;84:302–308.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moles MA, Scully C. Vesiculo-erosive oral mucosal disease – management with topical corticosteroids: (1) fundamental principles and specific agents available. J Dent Res. 2005;84:294–301.
   PubMed Web of Science ®Google Scholar
• Kalmar JR. Topical corticosteroids and oral vesiculo-erosive disease: where’s the beef? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89:395–396.
   PubMed Web of Science ®Google Scholar
• Noce CW, Gomes A, Shcaira V, et al. Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1163–1168.
   PubMed Web of Science ®Google Scholar
• Franca CM, Domingues-Martins M, Volpe A, et al. Severe oral manifestations of chronic graft-vs.-host disease. J Am Dent Assoc. 2001;132:1124–1127.
   PubMed Web of Science ®Google Scholar
• Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001;7:211–216.
   PubMed Web of Science ®Google Scholar
• Marable DR, Bowers LM, Stout TL, et al. Oral candidiasis following steroid therapy for oral lichen planus. Oral Dis. 2016;22:140–147.
   PubMed Web of Science ®Google Scholar
• Lozada-Nur F, Huang MZ, Zhou GA. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1991;71:283–287.
   PubMedGoogle Scholar
• Lozada-Nur F, Robinson J, Regezi JA. Oral hairy leukoplakia in nonimmunosuppressed patients. Report of four cases. Oral Surg Oral Med Oral Pathol. 1994;78:599–602.
   Web of Science ®Google Scholar
• Elad S, Or R, Garfunkel AA, et al. Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:308–311.
   PubMed Web of Science ®Google Scholar
• Sari I, Altuntas F, Kocyigit I, et al. The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol. 2007;82:349–356.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Moles MA, Morales P, Rodriguez-Archilla A, et al. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:264–270.
   PubMed Web of Science ®Google Scholar
• Decani S, Federighi V, Baruzzi E, et al. Latrogenic Cushing’s syndrome and topical steroid therapy: case series and review of the literature. J Dermatolog Treat. 2014;25:495–500.
   PubMed Web of Science ®Google Scholar
• Elad S, Or R, Shapira MY, et al. CO2 laser in oral graft-versus-host disease: a pilot study. Bone Marrow Transplant. 2003;32:1031–1034.
   PubMed Web of Science ®Google Scholar
• Wolff D, Anders V, Corio R, et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed. 2004;20:184–190.
   PubMed Web of Science ®Google Scholar
• Waller DG, Sampson AP, Renwick AG, et al. Corticosteroids (glucocorticoids and mineralocorticoids). In: Waller DG, Sampson AP, ed. Medical pharmacology and therapeutics. 4th edition ed. Edinburgh: Elsevier; 2014. p. 501–509.
   Google Scholar
• Eggleston TI, Ziccardi VB, Lumerman H. Graft-versus-host disease. Case report and discussion. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:692–696.
   PubMed Web of Science ®Google Scholar
• Thalen A, Brattsand R. Synthesis and anti-inflammatory properties of budesonide, a new non-halogenated glucocorticoid with high local activity. Arzneimittelforschung. 1979;29:1687–1690.
   PubMed Web of Science ®Google Scholar
• Zadik Y, Nakdimon I, Meyerowitz C, et al. Topical budesonide for severe oral chronic graft-versus-host disease. Am J Health Syst Pharm. 2014;71:181–182.
   PubMed Web of Science ®Google Scholar
• Epstein JB, Nantel S, Sheoltch SM. Topical azathioprine in the combined treatment of chronic oral graft-versus-host disease. Bone Marrow Transplant. 2000;25:683–687.
   PubMed Web of Science ®Google Scholar
• Mawardi H, Stevenson K, Gokani B, et al. Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant. 2010;45:1062–1067.
   PubMed Web of Science ®Google Scholar
• Utsman RA, Epstein JB, Elad S. Budesonide for local therapy of complex oral mucosal immune-mediated inflammatory diseases: case reports. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:e11–7.
   PubMed Web of Science ®Google Scholar
• Elad S, Horowitz R, Zadik Y. Supportive and palliative care in dentistry and oral medicine. In: Smith HS, Pilitsis J, ed. The art and science of palliative medicine. Hong Kong: AME Publishing Company; 2014. p. 385–405.
   Google Scholar